empesertib

Drug Overview

Empesertib is an investigational medication being studied for its ability to stop cancer cells from dividing. It is considered a Targeted Therapy and a “Smart Drug” because it focuses on a specific protein inside cells rather than attacking all cells in the body.

• Generic Name: Empesertib (also known as BAY 1161961)
• US Brand Names: None (Currently an Investigational Drug)
• Drug Class: Mps1 (Monopolar Spindle 1) Kinase Inhibitor; also known as a TTK inhibitor.
• Route of Administration: Oral (taken by mouth as a tablet).
• FDA Approval Status: Investigational. Empesertib is not yet approved by the FDA for standard medical use and is currently available only to patients participating in clinical trials.
  
  Find out how empesertib targets cancer cells. Our specialized hospital offers expert supportive care and clinical trials to optimize treatment outcomes.

What Is It and How Does It Work? (Mechanism of Action)

Empesertib works by disrupting the “quality control” system of a cell during division. To understand this, imagine a cell is a factory making a copy of itself. Before the factory splits into two, it must make sure all its instructions (chromosomes) are lined up perfectly.

At the molecular level, empesertib targets a protein called Mps1 (or TTK). In a healthy cell, Mps1 acts like a traffic light at the “Spindle Assembly Checkpoint” (SAC).

1. The Traffic Light: The SAC keeps the traffic light “Red” until all chromosomes are correctly attached to the machinery that pulls them apart.
2. The Interference: Empesertib binds to the Mps1 kinase. This forces the traffic light to turn “Green” prematurely, even if the chromosomes are not ready.
3. Chromosomal Chaos: Because the cell divides before it is ready, the chromosomes are pulled apart unevenly. This leads to a state called aneuploidy (an incorrect number of chromosomes).
4. Cell Death: Cancer cells are very sensitive to this level of chaos. The severe errors in division lead to “mitotic catastrophe,” which causes the cancer cell to self-destruct.

By blocking Mps1, empesertib prevents cancer cells from successfully multiplying, which can help shrink tumors or stop them from growing.

FDA Approved Clinical Indications

As empesertib is currently in the research phase, it does not have any FDA-approved indications. It is currently being studied for the following:

Oncological uses (Investigational):

• Advanced Solid Tumors: This includes various cancers that have spread or have not responded to other treatments.
• Triple-Negative Breast Cancer: Investigated as a potential target for this aggressive form of cancer.
• Colorectal Cancer: Studied in combination with other anti-cancer agents.

Non-oncological uses:

• There are currently no non-cancer uses being researched for this medication.

Dosage and Administration Protocols

Because empesertib is used in clinical trials, the dosage is strictly managed by study doctors. The doses are often adjusted to find the best balance between killing cancer and keeping the patient safe.

Dose Adjustments:

• Hepatic/Renal Insufficiency: In early studies, patients with severe liver or kidney problems are usually excluded. Specific dose adjustment rules for these groups are still being determined based on ongoing data.

Clinical Efficacy and Research Results

Research conducted between 2020 and 2025 has focused on the safety and early effectiveness of empesertib, particularly in patients who have failed multiple other treatments.

• Safety and Stability: In Phase I trials, empesertib demonstrated a manageable safety profile. A significant portion of patients achieved Stable Disease (SD), meaning their tumors did not grow larger during the treatment period.
• Numerical Data: In early cohorts, the Disease Control Rate (DCR) has been observed in approximately 20% to 30% of patients with heavily pre-treated solid tumors.
• Combination Potential: Recent data suggests that empesertib may work more effectively when combined with other chemotherapy drugs (like paclitaxel), as it makes cancer cells even more vulnerable to division errors.

Safety Profile and Side Effects

Like all powerful medications, empesertib can cause side effects. Because it affects cell division, it can impact healthy cells that divide quickly, such as blood cells.

Black Box Warning:

• None. (As an investigational drug, it has not yet been assigned a formal Black Box Warning).

Common side effects (>10%)

• Gastrointestinal Issues: Nausea, vomiting, and diarrhea.
• Fatigue: A general feeling of tiredness or lack of energy.
• Neutropenia: A decrease in white blood cells, which can increase the risk of infection.
• Alopecia: Thinning of hair or hair loss.

Serious adverse events

• Bone Marrow Suppression: A significant drop in blood counts that may require a pause in treatment or a blood transfusion.
• Severe Electrolyte Imbalance: Changes in the levels of salt and minerals in the blood.

Management Strategies:

• For Nausea: Doctors typically prescribe anti-nausea medications before the dose.
• For Low Blood Counts: Regular blood tests are performed. If counts get too low, the doctor may delay the next dose to let the body recover.

Research Areas

In the 2024–2025 research landscape, empesertib is being explored as a “priming agent.” Scientists are looking at how this drug can be used alongside Immunotherapy. By causing cancer cells to have the wrong number of chromosomes, the cells may release signals that “wake up” the immune system, making it easier for the body’s natural defenses to find and attack the tumor.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Complete Blood Count (CBC): To ensure blood levels are safe before starting.
• Comprehensive Metabolic Panel (CMP): To check liver and kidney function.
• Baseline Imaging: A CT or MRI scan to measure the size of the tumor.

Precautions during treatment

• Infection Risk: Because the drug can lower white blood cell counts, patients should avoid contact with sick individuals and wash their hands frequently.
• Hydration: Drinking plenty of water is essential to help the kidneys process the medication.

“Do’s and Don’ts” list

• DO take the medication at the exact time prescribed by your trial coordinator.
• DO report any fever over 38°C (100.4°F) immediately to your medical team.
• DON’T take any new supplements or herbal medicines without asking your doctor, as they may interfere with the study drug.
• DON’T skip blood test appointments; these are vital for your safety.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Empesertib is an experimental drug and is only available through clinical trials. Always consult with a qualified oncologist or healthcare professional regarding your diagnosis and treatment options. If you are experiencing a medical emergency, contact your local emergency services immediately.